Below the Skin's Outer Layer, Past the Gut's Absorption Barrier
How drug-delivery technology from a pharmaceutical research lab became cosmetic and food ingredients — Binotec's nano-delivery platforms, seen through three US patents

"Patented nano-delivery technology" has long been a routine line in cosmetic ingredient catalogs, and ingredient buyers' questions have become correspondingly specific: which patents, how small are the particles and how much do they carry, and has any of it been measured in human skin or human blood?
Binotec Co., Ltd. (CEO Yu-mi Kim), a nano drug-delivery technology company that opened a GMP plant in Gyeongsan, North Gyeongsang Province, last July, is one of the few companies able to answer all three on paper. This report draws on the company's English technical catalog, US and European patent records, a human clinical paper in an international journal, and finished-product test reports reviewed by our editorial team.
Origins in a pharmaceutical laboratory
Binotec's technology grew out of drug delivery systems (DDS) used in pharmaceuticals — packaging an active compound in a carrier so that it reaches its target before it is degraded or cleared. CEO Yu-mi Kim completed postdoctoral research at Georgia Tech in the US and in dentistry at Kyungpook National University before developing carriers as a principal researcher at CJ CheilJedang's pharmaceutical research institute; her work in the field spans 25 years. Founded in 2014 as Celize Cosmetic and renamed Binotec in 2018, the company chose to apply those principles to cosmetic actives and food ingredients.
The problem it addresses is simple to state. Skin has a tough outer layer, the stratum corneum, that blocks outside substances; the gut has an absorption barrier that keeps out compounds that do not dissolve well in water. However much of an ingredient is added to a formula, the amount that actually reaches the target layer often falls far short. Binotec addresses the two barriers with two distinct carrier families.
"The value of a delivery technology lies not in how much of an ingredient you put in, but in how precisely it arrives." — Yu-mi Kim, CEO, Binotec
Transdermal delivery: Hydroethosome® and five derivative carriers
Hydroethosome® encapsulates an active together with a hydrogel inside nano-scale lipid vesicles (ethosomes) and carries it into the skin. Patented in Korea in 2017 (KR 10-1810160), it was granted a US patent in September 2022 (US 11,452,679 B2) and has been filed in Thailand and Germany via PCT. The company credits the hydrogel with raising both the stability and the encapsulation rate of the ingredient.

Several derivative carriers have been built on the platform, each designed for the ingredient it carries. The specifications published in the company's 2024 English technical catalog are as follows.
| Carrier | Payload | Particle size · encapsulation | Evidence · IP |
|---|---|---|---|
| HydroDNA™ | Salmon-derived PDRN (Sodium DNA) | ≈ 40 nm · >90% encapsulated | KR 10-2678046 · Franz-cell skin absorption test |
| Hyalutosome™ | Low-molecular-weight hyaluronic acid | ≈ 40 nm | KR application 10-2021-0191800 · Franz-cell test |
| Triaction peptosome® | Three peptides | ≈ 160 nm | Hydroethosome® platform |
| Multisome® Licorice | Licorice root extract (glycyrrhizic acid) | ≈ 120 nm | Co-encapsulation of multiple actives |
| Hydropartisome® | Copper tripeptide and other scalp actives | 200–250 nm solid lipid nanoparticles; follicular route, sustained release | KR 10-2037354 · 10-2190935 · US 11,826,474 B2 |
Two points deserve a buyer's attention. First, PDRN — a DNA fragment whose negative charge makes it notoriously difficult to hold stably in lipid vesicles — is encapsulated at about 40 nm with better than 90% efficiency. Second, particle size on the same platform is deliberately varied from 40 nm for hyaluronic acid to 250 nm for follicle-targeted solid lipid particles, according to where the active needs to go.

Skin penetration was documented in-house by Franz-cell testing, and at finished-product level by third-party testing: for REPOVE Solution B, the Korea Institute of Dermatological Sciences measured a 150% increase in skin absorption rate, and 223% increases in absorption speed and depth, 30 minutes after application.

Oral delivery: Absosome™, and numbers measured in people
For ingredients taken by mouth, Absosome™ coats nano-lipid particles with multiple layers of materials such as chitosan and polyglutamic acid, shielding the payload through gastric acid and digestion and assisting uptake in the intestine. This multi-coated nanoparticle technology was granted a US patent in 2025 (US 12,318,462 B2) and a European patent (EP 3995126), validated in Germany, the United Kingdom and France.
Oral-delivery claims are frequently supported only by animal data. Binotec has published the results of a human pharmacokinetic study in an international journal. At the Efficacy Evaluation Center of Jeonbuk National University Hospital, 20 healthy adult men were divided into two groups: one took 400 mg of HYDROCUMIN™, curcumin encapsulated in Absosome™; the other took 2,000 mg of conventional curcumin. Peak blood concentration (Cmax) was 445.15 versus 38.30, and total blood exposure (AUC) 2,477 versus 561. Even at one-fifth the dose, AUC was 4.4 times higher — about 23 times higher on an equal-dose basis. The results were published in Scientific Reports in 2026. An earlier animal study reported a 109-fold AUC difference; that result is preclinical.

The company is explicit that these are absorption metrics and do not imply any specific health effect. What an overseas buyer can review alongside the ingredient specification is human data with a named institution, subject numbers, doses and endpoints on the record.
Reading the patent portfolio
| Jurisdiction | Number | Subject | Status |
|---|---|---|---|
| United States | US 11,452,679 B2 | Hydroethosome® transdermal carrier | Granted 27 Sep 2022 |
| United States | US 11,826,474 B2 | Nano-lipid carrier (Hydropartisome® family) | Granted |
| United States | US 12,318,462 B2 | Multi-coated nanoparticles (Absosome™ family) | Granted 2025 |
| Europe | EP 3995126 | Multi-coated nanoparticles | Granted · validated DE / GB / FR |
| Korea | 18 patents | Carrier, fermentation and extraction technologies | Granted |
| International | PCT/KR2018/002808 · TH 1901001249 · DE 11 2018 003 377.5 | Hydroethosome® filings | Pending |
Nano-carriers are not a new idea; the field has developed continuously since liposomes were first described in the 1960s. What Binotec offers as its point of difference is the integration of carrier, fermentation and extraction technologies within one company, linking ingredient development to finished-product manufacture, with the work documented in patents and ten published papers — from a 2019 ethosome transdermal study in the Journal of Drug Delivery Science and Technology to the 2026 human study.
Three routes open to buyers

Binotec currently has 19 cosmetic ingredients and five food ingredients, and the carriers described above were first used in its own skincare brand REPOVE and inner-beauty brand ABSOVE. Three forms of collaboration are open to overseas brands: supply of encapsulated ingredients; joint development in which a partner's own active is encapsulated in a Binotec carrier; and OEM/ODM manufacture at the Gyeongsan plant, which has production history for EU CPNP-notified and MUI Halal-certified products.
"On the strength of technology that can be verified through patents and published papers, we intend to broaden ingredient supply, joint development and manufacturing partnerships with overseas brands," Kim said.
This series introduces Binotec's technologies and products one at a time, in seven languages. The next article follows the Hydroethosome® platform through its sixth generation and the development of HydroDNA™.
About Binotec
Binotec Co., Ltd. is a Daegu-based bio company applying nano-delivery science to cosmetic and food ingredients. Its platforms include the transdermal carrier Hydroethosome®, the oral carrier Absosome™, the fermentation platform Absobiome™ and the high-concentration extraction technology Absotraction™, and the company holds 18 Korean patents, three US patents and one European patent. Binotec was named to Korea's "Innovative Companies 1000" by the Ministry of Science and ICT and received the Minister of SMEs and Startups Award for venture promotion in 2024. It opened a GMP plant in Gyeongsan in July 2026, was an official sponsor of APEC 2025, and exhibited at CES 2026 and Cosmoprof Bologna 2026. binotec.co.kr
Media contact
Media Division, FOB Holdings · aninyoul@fobholdings.co.kr · news.fobholdings.co.kr
This article is also available in: 한국어 · English · Français · 日本語 · हिन्दी · 简体中文 · العربية